acumapimod
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01332097)
Timeline
Indications
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(C(=O)NC2CC2)cc1-n1ncc(C(=O)c2cccc(C#N)c2)c1N- Mol. weight
- 385.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314397 ↗
- ChEMBLCHEMBL3545226 ↗
Also known as
- acumapimod
- acumapimod
- bct197
- bct197
- bct-197
- bct-197
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03498170 | Phase 1 | Mar 19, 2018 | Mereo BioPharma |
| NCT02926326 | Phase 1 | Sep 1, 2016 | Mereo BioPharma |
| NCT02700919 | Phase 2 | Apr 1, 2016 | Mereo BioPharma |
| NCT01336959 | Phase 2 | Sep 1, 2011 | Novartis |
| NCT01332097 | Phase 2 | Mar 1, 2011 | Novartis |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mereo BioPharma | For profit | 3 | 3 | 2 | 2016 |
| Novartis | For profit | 2 | 2 | 1 | 2011 |
2 organizations
Page 1 / 1